What New Developments Are There in the Treatment of Ovarian Cancer?

Read Transcript

Over the past 15 years or so 15, 20 years, we have said okay what are the genetic abnormalities in cancers and we've been defining those genetic abnormalities and those pathways and elucidating those pathways. What are the cellular pathways that lead a cancer to turn into a cancer cell or a malignant cell. We're now at a time we're like how do we impact those pathways?

What are the medications that we can use what are the compounds that we can use to impact how we alter those pathways and how can we combine those medications or compounds to hit that cancer cell so I think that we're in a transition time now where we've gone from defining the genetic abnormalities to how do we impact the genetic abnormalities so in my time when I started in oncology in my training 25 years ago we looked at a cell underneath a microscope and we said okay this is an ovarian cancer cell and these are the medications that were treating it, we then went to drug sensitivity testing, well let's what specific compounds the cancer cell is sensitive to to now defining the genetic abnormalities of that specific cancer cell so I can take patient's piece of tissue and I can send it off to different companies and they can give a whole litany of genes that are aberrantly or abnormally expressed and proteins that are abnormally expressed and then they can give me a list of compounds based on the data that may be active for that cancer cell. Now we're not at a time yet where we're using that information on a widespread basis we're still using our standard compounds combined with some of the biologic therapies like the antiangiogenesis therapies but we're transitioning I think into a time now where we're beginning to look at those specific abnormalities of that specific cancer cell and what we call more personalized medicine.

So I've seen that transition over the past 25 years.